Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody–Drug Conjugate for the Treatment of Cancer

Antibody–drug conjugates (ADC) achieve targeted drug delivery to a tumor and have demonstrated clinical success in many tumor types. The activity and safety profile of an ADC depends on its construction: antibody, payload, linker, and conjugation method, as well as the number of payload drugs per an...

Descripción completa

Detalles Bibliográficos
Autores principales: Toader, Dorin, Fessler, Shawn P., Collins, Scott D., Conlon, Patrick R., Bollu, Reddy, Catcott, Kalli C., Chin, Chen-Ni, Dirksen, Anouk, Du, Bingfan, Duvall, Jeremy R., Higgins, Stacy, Kozytska, Mariya V., Bellovoda, Kamela, Faircloth, Chelsey, Lee, David, Li, Fu, Qin, Liuliang, Routhier, Caitlin, Shaw, Pamela, Stevenson, Cheri A., Wang, Jason, Wongthida, Phonphimon, Ter-Ovanesyan, Elena, Ditty, Elizabeth, Bradley, Stephen P., Xu, Ling, Yin, Mao, Yurkovetskiy, Alexandr V., Mosher, Rebecca, Damelin, Marc, Lowinger, Timothy B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
First Disclosures
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477829/
https://www.ncbi.nlm.nih.gov/pubmed/37294948
http://dx.doi.org/10.1158/1535-7163.MCT-22-0786

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10477829/
https://www.ncbi.nlm.nih.gov/pubmed/37294948
http://dx.doi.org/10.1158/1535-7163.MCT-22-0786

Ejemplares similares